Hence, multiple Tyk2 inhibitors are being evaluated for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis, hidradenitis suppurativa, inflammatory bowel disease, dermatomyositis, and SLE [10,29,30]. Here, TYK2 is linked to systemic lupus erythematosus.